Overview

Phase I Study of OPC-61815

Status:
Completed
Trial end date:
2018-07-05
Target enrollment:
Participant gender:
Summary
To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on QT/QTc interval in healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination